Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on June 2, 2025
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
GlobeNewswire
·
June 2, 2025
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical …
FDA expands XENOVIEW® indication to include children from six years of age
GlobeNewswire
·
June 2, 2025
DURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that the …
Pinnacle Treatment Centers Introduces New Opioid Treatment Options in California: Sublocade and Vivitrol
GlobeNewswire
·
June 2, 2025
Canoga Park, California, June 02, 2025 (GLOBE NEWSWIRE) -- Aegis Treatment Centers, part of the Pinnacle Treatment Centers Family of Companies, a leader in providing evidence-based care for individuals struggling with Substance Use Disorder (SUD), is …
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
GlobeNewswire
·
June 2, 2025
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical data demonstrate an 87% overall response rate in patients with metastatic prostate cancer Results …
TELA Bio Appoints Jeffrey Blizard as President
GlobeNewswire
·
June 2, 2025
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President …
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial …
SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025
GlobeNewswire
·
June 2, 2025
FORT LAUDERDALE, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
LogicMark, Inc. Common Stock to Commence Trading on OTC Markets as the Company Continues Advancing Growth Initiatives
GlobeNewswire
·
June 2, 2025
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (the “Company”), a provider of personal emergency response systems (“PERS”), health communication devices, and technology for the growing care economy, today announced that it expects that …
NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking
GlobeNewswire
·
June 2, 2025
BANGKOK, June 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced plans …
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
GlobeNewswire
·
June 2, 2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, …
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
GlobeNewswire
·
June 2, 2025
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly …
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewswire
·
June 2, 2025
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines …
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
GlobeNewswire
·
June 2, 2025
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic biotechnology company, today announced the closing of a $ …
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
GlobeNewswire
·
June 2, 2025
Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25 …
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
GlobeNewswire
·
June 2, 2025
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
·
June 2, 2025
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
GlobeNewswire
·
June 2, 2025
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- What if everything we thought we knew about pain was wrong? Today, more than 1 in 5 Americans live with chronic pain, and too often, their pain is met with silence, surgery, or a prescription pad. Now, …
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
GlobeNewswire
·
June 2, 2025
-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of …
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today …